StockData
Alnylam Pharmaceuticals, Inc. logo

Alnylam Pharmaceuticals, Inc.

ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3049% below fair value
$149.40−7.10 (-4.54%)

Close on Nov 18, 2026Market cap $20.01BP/E 7.8Yield –

Alnylam Pharmaceuticals CEO Total Annual Compensation by Year

CEO Total Annual Compensation (DEF 14A Pay Ratio Disclosure, $) ($)

Alnylam Pharmaceuticals CEO Total Annual Compensation: $14,867,600 in FY2025, up 29.4% from a year earlier. That is the highest of the 8 years on record here.

Latest, FY2025
14,867,600
Period ended Dec 31, 2025
Change on a year earlier
+29.4%
11,492,970 in FY2024
History
8 years
Since FY2018
Sources
8
Documents cited below

Where the FY2025 figure comes from

“We calculated the 2025 compensation for our median employee of $312,180 in the same manner we determine the annual total compensation of our NEOs for purposes of the Summary Compensation Table. Dr. Greenstreet’s 2025 compensation as disclosed in the Summary Compensation Table is $14,867,600. As a result, our CEO to median employee pay ratio for 2025 is 48:1”

Source: Alnylam Form DEF 14A (2026 Proxy Statement (DEF 14A), filed 2026-04-06) ↗

annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). Alnylam Pharmaceuticals CEO Total Annual Compensation ($), annual FY2018–FY2025 [Data set]. Compiled from Alnylam Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/alny/kpis/proxy-ceo-total-comp

See every metric in the Alnylam Pharmaceuticals KPI table. Data updated Nov 10, 2026.

See a number that looks wrong?